A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

NCT05420324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Mucosal Melanoma

Interventions

DRUG: YH003
DRUG: Pembrolizumab
DRUG: albumin paclitaxel

Sponsor

Eucure (Beijing) Biopharma Co., Ltd